Aratana Therapeutics Inc (PETX) was Resumed by Jefferies to “Buy”. Jefferies advised their investors in a research report released on Aug 19, 2016.
On the company’s financial health, Aratana Therapeutics Inc reported $0.61 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.42.Analysts expectations of $ .12.During the same quarter in the previous year, the company posted $-0.23 EPS.
Aratana Therapeutics Inc closed down -0.02 points or -0.22% at $8.96 with 8,48,500 shares getting traded on Wednesday. Post opening the session at $8.99, the shares hit an intraday low of $8.68 and an intraday high of $9.055 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Aug 10, 2016, Peter Steven St (PRESIDENT AND CEO) sold 50,000 shares at $9.25 per share price. According to the SEC, on Jun 28, 2016, Julia A Stephanus (CHIEF COMMERCIAL OFFICER) sold 30,000 shares at $6.25 per share price. On Jun 13, 2016, Ernst Heinen (Chief Development Officer) sold 15,000 shares at $6.72 per share price, according to the Form-4 filing with the securities and exchange commission.
Aratana Therapeutics Inc. is a pet therapeutics company focused on licensing developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions such as pain and inflammation stimulation of appetite cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs or both. The Company’s target indications include pain and inflammation associated with osteoarthritis inappetence post-operative pain lymphoma osteosarcoma atopic dermatitis ocular herpes and feline immunodeficiency virus. The Company’s most advanced products from a development and commercialization perspective AT-004 and AT-005 are monoclonal antibodies (MAbs) for treating lymphoma in dogs.